Healthcare [ 3/11 ] | Biotechnology [ 38/157 ]
CA | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 8, 22 | 0.08
Increased by
+900.00%
|
0.05
Increased by
+1.20 K%
|
Aug 9, 22 | -0.02
Decreased by
-105.41%
|
-0.02 |
May 10, 22 | 0.54
Increased by
+22.73%
|
0.38
Increased by
+110.80%
|
Nov 9, 21 | -0.08 | -0.05
Decreased by
-1.20 K%
|
Aug 12, 21 | -0.01 | 0.08
Decreased by
-1.41 K%
|
May 13, 21 | 0.37 | 0.38
Decreased by
-6.93%
|
Mar 29, 21 | 0.44 | 0.61
Decreased by
-45.69%
|
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Sep 30, 22 | 101.38 M
Increased by
+1.74 K%
|
26.62 M
Increased by
+224.53%
|
Increased by
+26.26%
Increased by
+106.77%
|
Jun 30, 22 | 45.92 M
Increased by
+66.11%
|
-6.79 M
Decreased by
-192.08%
|
Decreased by
-14.78%
Decreased by
-75.84%
|
Mar 31, 22 | 316.58 M
Increased by
+56.15%
|
168.57 M
Increased by
+43.81%
|
Increased by
+53.25%
Decreased by
-7.90%
|
Dec 31, 21 | 139.33 M
Decreased by
-32.98%
|
59.95 M
Decreased by
-48.76%
|
Increased by
+43.03%
Decreased by
-23.54%
|
Sep 30, 21 | 5.51 M
Decreased by
-41.17%
|
-21.38 M
Decreased by
-693.91%
|
Decreased by
-388.16%
Decreased by
-1.25 K%
|
Jun 30, 21 | 27.64 M
Increased by
+146.20%
|
-2.32 M
Decreased by
-134.66%
|
Decreased by
-8.40%
Decreased by
-114.08%
|
Mar 31, 21 | 202.74 M
Increased by
+4.25 K%
|
117.22 M
Increased by
+5.70 K%
|
Increased by
+57.82%
Increased by
+228.65%
|
Dec 31, 20 | 207.91 M
Increased by
+6.39 K%
|
117.00 M
Increased by
+7.23 K%
|
Increased by
+56.27%
Increased by
+209.82%
|
Rank | ETF | Shares | Market Value | Weight % in ETF |
---|
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.